Eaton and Xendee Collaborate to Optimize Microgrid Performance Using AI-Powered Tools for Greater Energy Savings, Security and Sustainability
8.9.2025 14:33:00 CEST | Business Wire | Press release
Combined solution further automates cloud-based energy optimization and advances resilience, efficiency and operating costs for both new and existing microgrid deploymentsAt RE+ 2025, Eaton to showcase microgrid capabilities with Xendee and both companies will have featured speaking engagements
Intelligent power management company Eaton is collaborating with Xendee Corporation, a provider of the leading design and operation platform for distributed energy and microgrid systems. Xendee’s cutting-edge microgrid modeling and operations platform combined with Eaton’s engineering expertise and proven power distribution technologies deliver a fully integrated microgrid solution. Eaton led a Series B financing round for Xendee Corporation to further accelerate the deployment of artificial intelligence (AI) powered tools for distributed energy resources (DERs), and to help power the next phase of Xendee’s growth. Together, the companies will provide customers a streamlined path to design, deploy and operate highly efficient, resilient microgrids and DERs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908520968/en/

Eaton is collaborating with Xendee to optimize microgrid performance and drive greater energy resilience, efficiency and cost savings. (Image credit: Eaton)
According to the International Energy Agency, adoption of AI across the buildings sector alone could save up to 300-terawatt-hours (TWh) of energy annually. Eaton and Xendee will help customers leverage AI for new and existing microgrids using onsite energy sources, to sustainably meet energy demands, strengthen energy resilience and drive substantial operating cost savings.
“Together with Xendee, we’re unlocking new ways to help customers maximize the functionality and value of their microgrid investments across North America and Europe,” said Angie McMillin, president of Energy Solutions and Services at Eaton. “We’re confident that uniting Eaton’s proven microgrid expertise, intelligent power management solutions and services with Xendee’s advanced digital optimization technology will better position microgrid operators to seize the opportunities created by the energy transition.”
“Our partnership with Eaton allows us to provide a full-suite solution for microgrids by combining Xendee’s design and Model Predictive Control software and distributed energy modeling expertise with Eaton’s control hardware and expertise, providing microgrid project owners and developers what they need to implement systems at scale and maximize their return on assets,” said Adib Nasle, Co-Founder and CEO of Xendee.
The collaboration couples Eaton microgrid hardware and engineering service capabilities with Xendee’s AI-powered Model Predictive Control software, which continually evaluates and optimizes microgrid systems with AI forecasted alternatives. Xendee’s solution is hardware agnostic, allowing DER operators to seamlessly manage over 27 different types of technologies, including solar, battery energy storage systems, nuclear, linear generators, and combined heat and power. The solution will unlock real-time operational adjustments for microgrid systems that help lead to significant cost savings, enhanced resilience, reduced emissions and extended equipment lifespans.
Eaton will showcase its microgrid capabilities and expertise in booth #V8071, and lead three microgrid-focused educational sessions, during RE+ 2025. Learn more about how the company’s Everything as a Grid approach is helping communities and businesses reduce the cost and environmental impact of energy.
Xendee will lead two sessions at RE+ 2025, focused on a standardized and phased approach to powering data centers with distributed energy, and why developers are transitioning from PV-based systems to microgrids. Learn more about how Xendee’s approach to powering data centers streamlines the creation of an optimal multi-year strategy for lower costs and maximum resilience.
About Xendee Corporation
Xendee is an award-winning software platform built to integrate the feasibility analysis and proposal building, portfolio assessment, detailed engineering, and operation of Distributed Energy Resources and EV fast-charging infrastructure. It is the only integrated provider of microgrid design and Artificial Intelligence-based microgrid operation optimization software. Xendee’s techno-economic algorithms can produce an ideal investment solution and operation schedule to meet organizational goals which can include reducing costs, cutting CO2 emissions, and increasing resilience. Explore how Xendee can empower your organization by setting up a call with us at xendee.com/demo.
About Eaton
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re helping to solve the world’s most urgent power management challenges and building a more sustainable society for people today and generations to come.
Founded in 1911, Eaton has continuously evolved to meet the changing and expanding needs of our stakeholders. With revenues of nearly $25 billion in 2024, the company serves customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908520968/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom